Tilray's $915M Revenue Record Is Being Ignored-Why TLRY Still Looks Cheap

Record revenue and debt repair have not reset the market's view

Why the stock still looks discounted

Tilray just delivered record revenue of over $915 million and net debt reduced to less than $1 million. Even so, the stock remains down 81.9% year to date. That gap between fundamentals and price is the setup: Tilray looks less like a clean deep-value name and more like a business still carrying a fear discount.

The improvement is broader than a single headline. In fiscal Q3, Tilray reported record net revenue, record gross profit, record international cannabis revenue. The same release also showed combined Canadian adult-use and medical cannabis net revenue rising 8% year over year. That matters because the improvement is showing up in operating economics, not just in messaging.

Tilray's revenue mix is broadening beyond the old cannabis label

Beverage and distribution are reducing sector dependence

Investors still frame Tilray too much as a cannabis-only company, even though the portfolio now spans several businesses with different drivers. In the latest full-year data, beverage revenue increased 6% to $254 million and distribution revenue increased 21% to $327.2 million. That matters because those segments do not carry the same policy sensitivity as mature cannabis markets.

A wider mix also changes the resilience profile. A company with meaningful beverage and distribution scale is less exposed to one weak Canadian harvest or one rough recreational cannabis quarter.

International cannabis is improving, not stagnating

For skeptics who still view cannabis as the weak link, the recent quarter still stands out. In fiscal Q3, international cannabis net revenue growth was 73%, cannabis flower sales volume increased 100% year over year, and combined Canadian adult-use and medical cannabis net revenue rose 8% year over year. Those are signs of operating improvement in the core segment, not just stability.

Balance-sheet repair is changing how the numbers behave

The clearest proof that execution is improving is the balance sheet. By the first fiscal quarter of 2026, Tilray had $265 million in cash, net debt reduced to $4 million, and net cash used in operations improved by $34 million year-over-year. Then in Q2, the company said it had moved to a net cash position with $292 million in cash and marketable securities.

That is more than cosmetic progress. It shows better operating discipline translating into financial flexibility.

Why investors still hesitate

The cannabis label still anchors sentiment

After record fiscal 2026 revenue of over $915 million, hesitation is still understandable. The fair bear case is that non-cannabis businesses are masking weak local economics in core cannabis. If that is true, the discount is deserved.

Part of the problem is categorization. Tilray is still listed in the Drug Manufacturers - Specialty & Generic industry bucket, which makes it easier for investors to treat the entire group as a single cannabis trade. When that happens, good news from beverage or distribution can get filtered through old fears.

Recent price action can exaggerate that effect. After TD Cowen cut its target to $5.00 while keeping a buy rating, Roth simultaneously upgraded Tilray and set a $10.00 target. The market often reacts more quickly to the negative headline than to the full range of estimates.

Wall Street's Hold rating reflects uncertainty, not disbelief

The current rating split is 3 buys, 3 holds, and 1 sell, with targets stretching from $5.00 to $20.00. That does not read like a market convinced Tilray is deteriorating. It reads like a market that sees improvement but is not yet willing to fully re-rate the stock.

What the next quarters need to prove

The signals that would strengthen the thesis

• The next report needs to show that record adjusted EBITDA of $61.1 million is a floor, not a peak.
• Cash conversion needs to keep supporting the balance sheet. Tilray was already in a net cash position, and year-end net debt reduced to less than $1 million showed the direction of travel.
• Management needs to keep validating the full-year story rather than giving investors a reason to treat one strong quarter as a one-off.

What would weaken the case

• If margins slip or cash flow fails to follow earnings, the market is likely to conclude the turnaround is only partial.
• If guidance softens while the stock remains near its weak range, sentiment can break faster than fundamentals.

The upside case is not just about better numbers. It is about narrowing the gap between Tilray's operating results and the market's labeling of the business.